• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Zimmer Biomet (ZBH) Dividend Move And OneStep Digital Recovery Partnership

    Simply Wall St·12/19/2025 22:33:19
    Listen to the news
    • Zimmer Biomet Holdings, Inc. announced in the past that its Board approved a fourth-quarter 2025 cash dividend of US$0.24 per share, payable on or about January 30, 2026, to stockholders of record as of December 30, 2025.
    • The company also revealed an exclusive collaboration with OneStep to embed smartphone-based gait and mobility analytics into its mymobility Care Management Platform, potentially deepening its role in post-surgery orthopedic recovery and remote monitoring.
    • We’ll now examine how integrating OneStep’s mobility analytics into Zimmer Biomet’s connected-care ecosystem could influence its broader investment narrative.

    These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

    Zimmer Biomet Holdings Investment Narrative Recap

    To own Zimmer Biomet, you need to believe in growing orthopedic procedure volumes, the company’s push into robotics and digital care, and its ability to protect margins despite pricing and reimbursement pressures. The new dividend affirmation and OneStep collaboration do not materially change the near term picture, where execution on recent acquisitions and analyst caution remain key catalysts and risks.

    The OneStep partnership is most relevant here because it strengthens Zimmer Biomet’s connected care ecosystem, tying directly into its digital health catalyst around mymobility and data driven surgical solutions. If this integration supports wider adoption of premium implants and remote monitoring tools, it could reinforce the longer term thesis that connected care and robotics can support more stable revenue and margin trends despite competitive and pricing headwinds.

    Yet while connected care is promising, investors should also be aware of rising competitive intensity in robotics and core orthopedics, where ...

    Read the full narrative on Zimmer Biomet Holdings (it's free!)

    Zimmer Biomet Holdings' narrative projects $9.2 billion revenue and $1.3 billion earnings by 2028. This requires 5.5% yearly revenue growth and about a $476.5 million earnings increase from $823.5 million today.

    Uncover how Zimmer Biomet Holdings' forecasts yield a $102.92 fair value, a 15% upside to its current price.

    Exploring Other Perspectives

    ZBH 1-Year Stock Price Chart
    ZBH 1-Year Stock Price Chart

    Four members of the Simply Wall St Community value Zimmer Biomet between US$95 and about US$165.95 per share, showing how far opinions can stretch. Set this against the ongoing risk that integration of acquisitions like Paragon 28 and Monogram could weigh on margins and free cash flow, and it becomes even more important to compare several independent views before deciding how this stock fits into your portfolio.

    Explore 4 other fair value estimates on Zimmer Biomet Holdings - why the stock might be worth just $95.00!

    Build Your Own Zimmer Biomet Holdings Narrative

    Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

    Looking For Alternative Opportunities?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.